Then, a little more than a week after McKinsey suggested ways to boost sales of OxyContin, the FDA—the agency most responsible for ensuring the safety of the country’s drug supply—rewarded McKinsey with a $2.6 million consulting contract with the Center for Drug Evaluation and Research, which regulates prescription and generic drugs, including OxyContin. The FDA contract called for McKinsey to “work with the office leadership, the program managers, and other key personnel to design, develop, and implement an operating model that ensures good communication both internally and externally.”
